Лучшие больницы для «Lung Cancer Treatment» в Хайдарабад, Индия

The cost of lung cancer treatment varies by modality and stage. In India, a VATS lobectomy (surgery alone, including hospital stay, anaesthesia, and standard medications) typically costs USD 6,000–12,000. A course of SBRT runs USD 4,000–8,000. A complete concurrent chemoradiotherapy programme (6–7 weeks) costs USD 8,000–18,000. First-line systemic therapy initiation (targeted agents or immunotherapy, per cycle) costs USD 1,500–5,000 per cycle depending on the drug. In the UAE (Dubai/Abu Dhabi), equivalent procedures cost approximately 60–100% more: VATS lobectomy USD 18,000–35,000; SBRT USD 15,000–28,000; concurrent CRT USD 22,000–55,000; and systemic therapy initiation USD 5,000–15,000 per cycle. Both destinations provide JCI-accredited hospitals, internationally trained thoracic oncologists, NGS-guided molecular profiling, and robotic surgical platforms. India offers the lowest cost globally for equivalent clinical quality, while the UAE offers premium private hospital environments and superior geographic convenience for patients from the GCC, East Africa, and the broader Arab world. GAF Healthcare provides a personalised itemised cost estimate within 48 hours of receiving your medical records, with no obligation to proceed.

Fit-to-fly timelines are modality-specific and are determined by your thoracic surgeon or oncologist at the treating centre. After VATS or robotic-assisted lobectomy or segmentectomy, most patients are cleared for international flight at 3 weeks post-surgery, provided chest X-ray confirms no residual pneumothorax, pain is controlled on oral analgesia, and there are no signs of DVT on clinical assessment. Long-haul flights carry an elevated risk of deep vein thrombosis (DVT) and pulmonary embolism after thoracic surgery; all surgical patients receive a prescription for low molecular weight heparin (LMWH) and compression stockings for the return journey. After open thoracotomy or pneumonectomy, the fit-to-fly timeline is extended to 5–6 weeks, contingent on wound healing, stable spirometry, and cardiologist clearance. After SBRT, patients are typically cleared to fly 2–3 weeks after the final fraction once acute radiation reactions have settled. After the first cycle of chemotherapy, patients must wait until bone marrow nadir recovery — usually Day 14–21 — with white blood cell count above 3.0 × 10⁹/L and platelets above 100 × 10⁹/L before long-haul travel. Patients on oral targeted therapy (e.g., osimertinib, alectinib) may travel once tolerating the medication without significant side effects, typically 2–3 weeks after initiation. GAF Healthcare issues a formal fit-to-fly certificate from the treating physician, which is accepted by airlines for boarding with medical documentation.

Success rates in lung cancer are stage- and modality-dependent and are best understood by specific disease scenario. For Stage I NSCLC treated with curative-intent VATS or robotic lobectomy, the 5-year overall survival rate is 70–90% (Stage IA3: 77–90%; Stage IB: 68–75% per IASLC data). SBRT for medically inoperable Stage I NSCLC achieves local control rates of 85–95% at 3 years, with 5-year overall survival of 40–60% (reflecting co-morbidities rather than oncological failure). For Stage II NSCLC with surgery ± adjuvant chemotherapy or osimertinib (ADAURA trial for EGFR-mutant disease, 88% DFS at 4 years), 5-year survival is 53–65%. For Stage III NSCLC managed with concurrent chemoradiotherapy plus durvalumab consolidation (PACIFIC regimen), median overall survival exceeds 47 months with a 5-year OS rate of approximately 42%. For Stage IV EGFR-mutant NSCLC treated with osimertinib, median progression-free survival is 18–25 months and median overall survival exceeds 38 months per the FLAURA data. For Stage IV ALK-rearranged NSCLC on alectinib, median PFS is 34 months. For high PD-L1 expressors (TPS ≥50%) on pembrolizumab monotherapy, 5-year OS rates of 31% have been reported in the KEYNOTE-024 trial — a remarkable benchmark for Stage IV disease. SCLC limited-stage achieves 5-year OS of 20–35% with concurrent chemoradiotherapy; extensive-stage SCLC median OS is 12–13 months with modern chemoimmunotherapy. GAF Healthcare's partner centres treat high volumes of thoracic oncology cases and submit outcomes data to international tumour registries, ensuring transparency and accountability.